Background. Left ventricular assist device (LVAD) implantation has become an effective treatment option for patients with severe heart failure awaiting transplantation. Significant infection rates have been reported among LVAD recipients. However, few reports have focused specifically on device infection, its treatment, and the impact of LVAD-related infection on clinical outcome.
For more than a decade, left ventricular assist device (LVAD) implantation has been an effective treatment option for patients with end-stage heart failure awaiting transplantation. Normalization of hemodynamics improves end-organ function, with ∼70% of patients surviving until heart transplantation [1] [2] [3] . In spite of this success, LVAD-related infection is a common complication that may delay or prevent transplantation in some patients, and it is a significant cause of death among nontransplant candidates who undergo LVAD implantation as long-term myocardial replacement therapy [3] . The most feared infectious complication, LVAD endocarditis, is associated with significant pretransplantation mortality [4, 5] . Few details concerning optimal management of LVAD-related infection appear in the literature. We present the microbiological findings, treatment, and clinical outcome of LVAD-related infection in patients who underwent LVAD implantation as a bridge to cardiac transplantation.
PATIENTS AND METHODS
All patients who underwent LVAD implantation at Rush University Medical Center (Chicago, IL) as a bridge to cardiac transplantation from December 1994 through August 2003 were included in this study. The medical record of each patient was reviewed retrospectively. Demographic and clinical information was collected from a prospective database and from the medical record of each patient, and this information included age, sex, underlying cardiomyopathy, presence of diabetes mel- litus, operative data, microbiological test results, and history of antibiotic therapy. This report includes previously published data on LVAD-related infection that occurred in the first 20 LVAD recipients at our institution [6] . This study was reviewed and approved by the Institutional Review Board of Rush University Medical Center. All patients received the pneumatically or electrically driven Heartmate LVAD (Thoratec). This device is a titanium-encased pump with an inflow conduit from the left ventricular apex and an outflow conduit to the ascending aorta. Within the device are 2 porcine valves that maintain unidirectional flow. LVAD implantation was performed via extended median sternotomy with pump placement into a pocket formed in the left rectus sheath. A driveline, tunneled from the pump, was connected to an external power source via an exit site initially ipsilateral to the pump in the lower abdominal wall. After May 1996, all drivelines exited at a site contralateral to the pump.
LVAD recipients received perioperative antibiotics that generally consisted of a 3-day course of vancomycin and a quinolone or an extended-spectrum b-lactam. After implantation, patients were placed in a private bed in the intensive care unit and were followed-up daily by an infectious disease physician during hospitalization. All patients implanted with a pneumatically driven device remained hospitalized until transplantation or death. Clinically stable patients implanted with an electrically driven device were discharged home and were evaluated weekly as outpatients.
Driveline exit site care consisted of daily sterile cleansing with povidone-iodine and isopropyl alcohol, dilute hydrogen peroxide, or chlorhexidene and placement of an occlusive dressing. Specific measures to secure driveline exit sites, such as abdominal binders, were not routinely used. All LVAD recipients who developed clinical signs and symptoms of infection were evaluated to identify the site of infection. Cultures of driveline exit site drainage fluid and blood samples were performed as clinically indicated. Device pocket samples were generally collected for culture at the time of surgical drainage. All LVAD-related infections were treated with systemic antimicrobial agents. At the time of explantation, a majority of the devices were disassembled, cultured, and examined by a pathologist.
LVAD-related infections were categorized as local infections, which included driveline and device pocket infections, or as bloodstream infections (BSI), which included LVAD endocarditis, LVAD-related BSI, and presumed LVAD-related BSI. Driveline infection was defined as localized purulent drainage from the abdominal wall exit site and isolation of у1 pathogen. Device pocket infection was defined as localized purulence in the subcutaneous space in which the LVAD was placed and the isolation of у1 pathogen. LVAD endocarditis was defined as the isolation of the same microorganism from 11 blood culture and histopathologic evidence of infection involving the inflow/ outflow conduits or the porcine valves at the time of transplantation or autopsy [7] . LVAD-related BSI was defined as the isolation of the same microorganism (based on species and antibiogram) from 11 blood culture and from samples obtained from the driveline exit site and/or LVAD pocket and/or from the explanted device in the absence of histopathologic evidence of device infection. Presumed LVAD-related BSI was defined as the isolation of the same microorganism from 11 blood culture without identification of another source. Patient characteristics were evaluated for association with LVAD-related infection by use of univariate and multivariate logistic regression analysis. Outcome measures for patients with LVAD-related infections were compared with those of patients without LVAD-related infections. Categorical variables were compared using Fisher's exact test, and continuous variables were compared using Student's t test. A 2-tailed P value of !.05 was considered to be statistically significant. Survival analysis was performed using Kaplan-Meyer statistics, and groups were compared using the log rank test. Data were analyzed using SPSS software, version 11 (SPSS Institute).
RESULTS
During the study period, 76 patients underwent LVAD implantation as a bridge to cardiac transplantation, for a total of 9466 LVAD-days. Forty-six episodes of LVAD-related infection developed in 38 patients, for an overall attack rate of 50% and an incidence of 4.9 LVAD-related infections per 1000 LVADdays. Twenty-nine episodes of LVAD-related BSI were diagnosed in 24 patients, for an attack rate of 32% and an incidence of 3.1 LVAD-related BSIs per 1000 LVAD-days.
The median time to diagnose any LVAD-related infection was 30 days (range, 5-419 days). Only 2 initial episodes of LVAD-related infection occurred 190 days after implantation. LVAD-related infection was diagnosed in 25 patients during hospitalization (in 15 of 34 patients with pneumatic devices and in 10 of 17 patients with vented electric devices). Twentysix patients with vented electric LVADs were discharged from the hospital with the device. Thirteen patients were diagnosed with LVAD-related infection as outpatients a median of 34 days after discharge (range, 2-419 days).
Gram-positive and gram-negative bacteria were identified in 
and Candida tropicalis).
No host factor was identified as significantly associated with the development of device-related infection (table 2) . However, subgroup analysis revealed that patients with LVAD-related BSI were more likely to have diabetes mellitus, compared with all other LVAD recipients (OR, 7.7; 95% 95% CI, 2.0-29.8).
Five patients in the group with LVAD-related infection did not survive to transplantation. Persistent sepsis with multiorgan failure caused by LVAD-related infection was the cause of death in 3 of these patients. One patient died from polymicrobial sepsis not related to the LVAD, and another patient died due to device-related mechanical failure. Seven deaths occurred before transplantation in the group without LVAD-related infection. Two patients died soon (!5 days) after LVAD implantation because of refractory cardiogenic shock, 3 patients died because of non-LVAD-related sepsis, 1 patient had device-related mechanical failure, and 1 patient died as a result of LVAD-associated hemorrhage.
LVAD-related infection delayed but did not prevent successful heart transplantation. Patients with LVAD-related infection had longer device support times than did patients without LVAD-related infection (mean duration
) and increased early mortality due to P p .064 a new infection ( ) in the group with LVAD-related P p .055 infection (table 3) . Seven patients who were treated for LVADrelated infection died due to a new infectious complication in the early posttransplantation period. In comparison, there was 1 death among patients without LVAD-related infection.
After transplantation, invasive vancomycin-resistant Enterococcus faecium (VREF) infection developed in 6 patients previously treated for LVAD-related infection (table 4). Four of these patients died. No invasive VREF infections were diagnosed in patients without LVAD-related infection ( , by P p .02 Fisher's exact test).
At the time of LVAD removal, interior device cultures were obtained from 31 of 38 patients treated for LVAD-related infection. Twelve patients had positive culture results. Eleven of these patients were considered to have results indicative of true or death. Twelve patients received limited courses of treatment (2-6 weeks). There were more cases of relapse, more LVAD superinfections, and longer LVAD support times among those who received limited antimicrobial therapy (table 5) . Further analysis revealed that limited treatment increased the risk for relapse and LVAD superinfection (figure 2). Because several patients in the continuous treatment group underwent transplantation soon after initiation of antimicrobial therapy, Kaplan-Meier estimates were again determined after censoring patients in the continuous treatment group who received !28 days of therapy. Again, limited therapy increased the risk for relapse and LVAD superinfection ( , by the log rank P p .0175 test). Those who experienced relapse or developed LVAD superinfection were less likely to undergo transplantation (P p , by Fisher's exact test). There were no differences between .04 the limited treatment group and the continuous treatment group in terms of the number of patients surviving to transplantation, the median length of hospitalization after transplantation, the number of deaths due to infection after transplantation, or the incidence of invasive VREF infection (table  5 ). The survival rates 1 year after transplantation were also similar (data not shown).
Six patients had a second distinct episode of LVAD-related infection (i.e., superinfection). All had cases of BSI. Three patients were not receiving antimicrobial therapy at the time of the second episode of LVAD-related infection. Three patients were receiving treatment to which the second bacterial isolate was resistant. The first and second isolates for each of these cases were as follows: E. faecalis and methicillin-resistant S.
epidermidis [MRSE] , methicillin-susceptible S. aureus [MSSA] and Corynebacterium striatum, and methicillin-susceptible S. epidermidis [MSSE] and Corynebacterium species. Four of 6 patients were treated with continuous antimicrobial therapy before, during, and after transplantation, and 1 of these patients experienced relapse (with MRSE infection). Two patients were treated with limited therapy (6 weeks). Both of these patients experienced relapse with bacteremia and died. One patient received a diagnosis of LVAD endocarditis due to Pseudomonas aeruginosa with infected thrombus involving the inflow conduit of the device. Table 6 summarizes the relationship between the duration of antimicrobial therapy and relapse for 43 of 46 episodes of LVAD-related infection. Relapse of LVAD-related infection was uncommon for those who received continuous treatment, occurring in 3 of 22 episodes of LVAD-related BSI and 0 of 7 episodes of local infection. The BSI relapses were due to MRSA in 1 case and MRSE in 2 cases. Relapse of MRSA bacteremia occurred 4 weeks into parenteral vancomycin therapy. This organism remained susceptible to vancomycin and required the addition of rifampin and gentamicin to the regimen to clear the bloodstream. Relapse of both episodes of MRSE bacteremia occurred after the completion of 8 weeks of parenteral vancomycin therapy and a switch to oral therapy. In the first case, relapse of MRSE bacteremia developed 126 days after the switch to oral therapy (i.e., after 55 days of linezolid therapy and 71 days of doxycycline therapy). This blood isolate remained susceptible to any previously administered antimicrobial agent. Resumption of intravenous therapy with vancomycin sterilized the bloodstream until transplantation. In the second case, relapse occurred 107 days after a switch to oral clindamycin, to which the MRSE blood isolate developed resistance. Despite parenteral antimicrobial therapy, near-continuous MRSE bacteremia developed, followed by septic shock, multiorgan failure, and death. LVAD endocarditis was diagnosed after the identification of multiple vegetations on the LVAD valve leaflets.
Ten relapses (5 cases of BSI and 5 cases of local infection) occurred among 14 episodes of LVAD-related infection (6 BSIs and 8 local infections) that were treated with a limited course of antimicrobial therapy (table 6) . Relapses were diagnosed a median of 12 days after antimicrobial therapy was discontinued (range, 2-89 days). Five (50%) of 10 relapses were due to S. aureus. All patients with episodes of LVAD-related infection due to S. aureus that were treated with a limited course of antimicrobial therapy experienced relapse. Among those with LVAD-related BSI, relapse occurred in 1 patient (with infection due to MRSE) who received treatment for 2 weeks and in 4 of 5 patients (2 with MSSA infection, 1 with VREF infection, and 1 with P. aeruginosa infection) who received treatment for 6 weeks. Among those with LVAD-related local infection, local relapse occurred in 2 (1 episode of MSSA infection and 1 episode of MSSE infection) of 3 episodes that were treated for 2 weeks, in 1 (an episode of MSSA infection) of 3 episodes that were treated for 4 weeks, and in 2 (1 episode of MRSA infection and 1 of infection with Acinetobacter species) of 2 episodes that were treated for 6 weeks. Three relapses of local infection were associated with bacteremia (1 episode of MSSA infection, 1 of MSSE infection, and 1 of infection due to Acinetobacter species). All 3 patients had negative blood culture results during initial local LVAD infection.
DISCUSSION
LVAD-related infection was a frequent and early complication among our LVAD recipients awaiting cardiac transplantation. Our observations are similar to reports from other transplant centers [8, 9] . The incidence rate of 3.1 cases of LVAD-related BSI per 1000 LVAD-days is comparable to the incidence of 3.0 cases per 1000 LVAD-days determined from data reported by the Cleveland Clinic [7] . More than 84% of our LVAD recipients survived to transplantation, which compares favorably to previous reports [1, 10] .
The predominance of gram-positive organisms causing LVAD-related infection was not unexpected [8, 11, 12] . S. epidermidis and S. aureus were the most frequently identified pathogens, responsible for 57% of all LVAD-related infections and 62% of LVAD-related BSIs. The driveline exit site appeared to be the major portal of entry in 18 of 30 episodes of LVADrelated BSI, as reflected by the isolation of the same organism from both the exit site and the bloodstream. Persistent local trauma and poor healing at the driveline exit site are common events after LVAD implantation, providing a site for skin organisms to initiate local infection. Underlying diabetes mellitus appeared to increase risk for LVAD-related BSI among our patients with device-related infection. Microvascular insufficiency and neutrophil dysfunction in individuals with diabetes mellitus are likely to be contributing factors to bacterial colonization and poor healing at the exit site, increasing the risk of invasive disease in these patients.
Although the optimal duration of antimicrobial therapy for LVAD-related infection is unknown, continuous antimicrobial therapy before, during, and after transplantation appears to be a more effective strategy than limited therapy to control LVADrelated infection. Limited antimicrobial therapy was rarely curative (with cure occurring in 4 of 14 episodes treated with limited therapy), was associated with more LVAD superinfections, may delay or prevent transplantation, was not associated with less antimicrobial use, and was likely to increase the overall cost of medical care. Continuous treatment appears to be indicated for all LVAD-related infections caused by S. aureus (and possibly for all LVAD-related BSIs). Also, LVAD-associated BSIs may be indistinguishable from LVAD-associated endocarditis, which was diagnosed in 5 (∼13%) of 38 patients and was associated with significant pretransplant mortality (40%). Medical therapy with emergent transplantation may be lifesaving for some of these patients [9, 13] . Continuous therapy may also be considered for patients with diabetes mellitus who have LVAD-associated infection, because of their increased risk for invasive disease.
One concern associated with prolonged antimicrobial therapy is the emergence of antibiotic-resistant organisms. The isolation of antibiotic-resistant organisms was uncommon in the pretransplantation period. However, the development of invasive VREF disease in the early posttransplantation period contributed to longer hospital stays ( ) and death due P p .064 to infection ( ) among patients treated for LVAD-re-P p .055 lated infection. The increased incidence of invasive VREF disease (18% vs. 0%; ) among patients treated for LVAD-P p .02 related infection may be due to longer stays in the intensive care unit before transplantation, as reflected by duration of LVAD support, and greater antibiotic exposure (particularly to vancomycin), compared with patients not treated for LVADrelated infection [14, 15] . Available antibiotic records indicated that 18 of 38 patients with LVAD-related infection received 14 weeks of vancomycin therapy, compared with 1 of 20 patients without LVAD-related infection.
There were several limitations to our study. As a single-center study, patient selection bias regarding candidacy for LVAD placement may have influenced outcomes before and after transplantation. In addition, the retrospective nature of this study may be associated with data-collection biases, but these biases were likely decreased by access to a prospectively collected database. One weakness of this study may be the nonspecificity of our definitions for LVAD-related infection. The use of molecular fingerprinting techniques on isolates obtained from exit sites, blood samples, and devices would have allowed more-definitive characterization of LVAD-related BSI and LVAD endocarditis and would have differentiated cases of relapse from new infections [16, 17] . The failure to collect all data on antibiotic use for both LVAD cohorts likely weakens our conclusion favoring continuous therapy for LVAD-related infection and any conclusion regarding invasive VREF infection.
In conclusion, LVAD-related infection was common among our patients. Gram-positive bacteria, particularly staphylococci, were the major pathogens associated with LVAD-related infection, and the driveline exit site was the major portal of entry for these organisms. LVAD-related infection delayed but did not prevent successful cardiac transplantation, nor did it negatively impact long-term survival. Continuous antimicrobial therapy before, during, and after transplantation may be superior to limited therapy for LVAD-related infection. However, patients with LVAD-related infection appear to be at increased risk for invasive VREF infection in the early period after transplantation.
